Chimeric ILT-Receptor engineered natural killer cell therapy (NKILT Therapeutics)

N/A

Report date: 2025/05/20 17:40:09

Base Information

Drug NameChimeric ILT-Receptor engineered natural killer cell therapy (NKILT Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNkilt Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNkilt Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A